Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers.

The oncologist - 5 Aug 2024

Shariff Bushra, Barnett Reagan M, Dayyani Farshid, Maron Steven B, Mcgriskin Rory, Klempner Samuel, Donderici Elifnur Yay, Zhang Nicole, Masannat Jude, Drusbosky Leylah M, Mehta Rutika

Abstract excerpt

PURPOSE: In addition to the existing biomarkers HER2 and PD-L1, FGFR2b has become an area of interest for the development of new targeted-based treatment. Given that clinical evaluation of FGFR2 targeted therapy is underway, we sought to elucidate the genomic landscape of FGFR2amp in gastroesophageal cancer (GEC) using a circulating tumor DNA (ctDNA) platform. MATERIALS AND METHODS: We retrospectively evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Esophageal Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38902956
DOI: 10.1093/oncolo/oyae061
PMCID: PMC11299948

Genes

FGFR2
CDH1
CTNNB1
RHOA
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers.PMID 38902956Read ↗

Real-world genomic landscape of FGFR2 amplifications and fusions in solid tumors: analysis of 4,953 patients using clinical-grade NGSSemantic proximity Read ↗

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal AdenocarcinomaSemantic proximity Read ↗

Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceSemantic proximity Read ↗

Impact of tissue-agnostic approvals for patients with gastrointestinal malignanciesSemantic proximity Read ↗

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.Semantic proximity Read ↗

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.Semantic proximity Read ↗

Real‐World Data Analysis of Genomic Alterations Detected by a Dual DNA – RNA Comprehensive Genomic Profiling TestSemantic proximity Read ↗

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric CancerSemantic proximity Read ↗

Unearthed Novel Molecular Phenotypes and Potential Therapeutic Targets in Esophagogastric AdenocarcinomaSemantic proximity Read ↗

Circulating Tumor DNA in Gastric and Gastroesophageal Junction CancerSemantic proximity Read ↗

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer TypesSemantic proximity Read ↗

ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.